Joseph A. Wahle
Joseph A. Wahle
Dr. Joe Wahle, pictured at his reception with Cancer Biology Program Director Ken Wright, defended his dissertation on October 19, 2007. Dr. Wahle initially joined the lab of Dr. Wayne Yokoyama, National Academy of Sciences Fellow, Washington University, St. Louis. He then became a scientist at Novo Nordisk in Seattle and is currently a Senior Principal Scientist at Boehringer Ingelheim.
Dr. Wahle's publication record while in the Program:
Wahle JA, Paraiso KHT, Costello AL, Goll EL, Sentman CL, Kerr WG. Cutting Edge: Dominance by an MHC-Independent Inhibitory Receptor Compromises NK Killing of Complex Targets. J Immunol. 2006 Jun 15;176(12):7165-9.
Wahle JA, Paraiso KH, Kendig RD, Lawrence HR, Chen L, Wu J, Kerr WG. Inappropriate recruitment and activity by the Src homology region 2 domain-containing phosphatase 1 (SHP1) is responsible for receptor dominance in the SHIP-deficient NK cell.J Immunol. 2007 Dec 15;179(12):8009-15.
Dr. Wahle's publication since graduation:
Elliott JM, Wahle JA, Yokoyama WM. MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment.J Exp Med. 2010 Sep 27;207(10):2073-9.
Hazen AL, Diks SH, Wahle JA, Fuhler GM, Peppelenbosch MP, Kerr WG. Major remodelling of the murine stem cell kinome following differentiation in the hematopoietic compartment. J Proteome Res. 2011 Aug 5;10(8):3542-50.
Sauer K, Park E, Siegemund S, French AR, Wahle JA, Sternberg L, Rigaud S, Jonsson AH, Yokoyama WM, Huang YH. Inositol tetrakisphosphate limits NK cell effector functions by controlling PI3K signaling. Blood. 2013 Jan 10;121(2):286-97. PMID: 23175687